2022-10-21-上交所-健民集团2022年第三季度报告_13页_315kb

Jianmin Pharmaceutical 2022 Q3 Summary

Overview

Jianmin Pharmaceutical Group Co., Ltd., securities code 600976, provided its Q3 2022 report. The company's board and directors assured the accuracy, truthfulness, and completeness of the report content.

Financial Highlights

• Revenue for Q3 2022 reached 967,670,625.04 yuan, showing an 18.98% year-over-year increase. Cumulative revenue for the first nine months was 2,794,971,258.49 yuan, rising by 7.25% compared to the same period in 2021.
• Net profit attributable to shareholders for Q3 2022 was 127,693,350.60 yuan, marking a 41.96% increase year-over-year. Cumulative net profit for the first nine months was 326,106,974.12 yuan, with a 26.84% year-over-year rise.
• Net profit after accounting for non-recurring items increased by 45.51% in Q3, driven by pharmaceutical sector growth and joint venture investments.
• Operating cash flow for the first nine months was 98,752,841.07 yuan, a 48.72% decline year-over-year, primarily due to higher procurement, personnel costs, and advertising expenses.
• Key ratios included a basic earnings per share (EPS) of 0.84 yuan in Q3 (42.37% increase) and a net asset yield of 6.96%.

Key Changes in Financial Indicators

• Profit growth factors: Expansion in pharmaceutical industrial sales and investment gains.
• Cash flow decrease: Attributed to increased inventory buildup and operational expenditures.

Shareholder Information

• As of September 2022, the company had 17,999 ordinary shares outstanding.
• Major shareholders included Huaili Pharmaceutical Group (24.13% stake), Huaili Group (3.32%), and various individuals and funds, with total ownership interests monitored.

Business and Strategy

• Growth driven by pharmaceutical business expansion, leveraging industrial segments and joint venture partnerships.
• Continuous investment and innovation supported revenue and profit increases.